US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
CytoMed Therapeutics Limited - Ordinary Shares
(NQ:
GDTC
)
0.9200
+0.0201 (+2.23%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about CytoMed Therapeutics Limited - Ordinary Shares
< Previous
1
2
Next >
CytoMed Therapeutics Ltd – An Emerging Star in Singapore’s Cancer Biotechnology Sector
July 15, 2026
Via
Get News
CytoMed Therapeutics Ltd (NASDAQ: GDTC) – A Rising Star in Singapore’s Cancer Biotechnology Sector
July 09, 2026
Via
Get News
CytoMed, a Singapore Biotech, Revolutionizes Cancer Treatment Using Donor Immune Cells
June 29, 2026
Via
Get News
CytoMed Therapeutics Ltd – A Rising Star in Singapore’s Cancer Biotechnology Sector
June 23, 2026
Via
Get News
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
January 28, 2026
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital
January 13, 2026
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia
December 08, 2025
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
November 18, 2025
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy
November 06, 2025
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%
October 22, 2025
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
October 14, 2025
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
October 02, 2025
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
August 28, 2025
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
August 18, 2025
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
July 21, 2025
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
April 28, 2025
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
February 06, 2025
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial
January 06, 2025
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
November 20, 2024
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
October 03, 2024
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
October 07, 2024
Completion of cash acquisition of licenced cord blood bank expanding CytoMed’s strategy to cord blood-derived biologics through its subsidiary, LongevityBank Pte Ltd
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
September 30, 2024
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
July 17, 2024
Another Patent Granted for CytoMed's Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells technology
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
Navigating the Challenges Facing an Aging Global Population: How CytoMed Seeks to Help Boost Cartilage Regeneration
March 20, 2024
The global population is rapidly aging. According to the World Population Prospects 2022 published by the United Nations, there were
Via
Spotlight Growth
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration
March 20, 2024
Via
ACCESSWIRE
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
March 18, 2024
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
March 04, 2024
CytoMed diversifies into regenerative medicine
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
January 29, 2024
The Company now has exclusive rights to a Malaysia, US and China patent
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
Singapore’s Journey to Becoming a Biotech Powerhouse
October 24, 2023
Singapore's Biotech Vision: From 2000 Onwards In 2000, Singapore embarked on an ambitious mission to establish itself as a leading
Via
Spotlight Growth
Topics
Economy
CytoMed Expands Research Collaboration into China After Entering Into MOU
August 29, 2023
Via
ACCESSWIRE
< Previous
1
2
Next >
